Navigation Links
BioDelivery Sciences to Present at the Stifel Nicolaus 2013 Healthcare Conference
Date:9/6/2013

RALEIGH, N.C., Sept. 6, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Stifel Nicolaus 2013 Healthcare Conference.  The presentation is scheduled for Wednesday, September 11, 2013 at 2:40 p.m. Eastern Time at the Four Seasons Hotel in Boston.

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO )

BDSI recently submitted a New Drug Application (NDA) for BUNAVAIL for the treatment of opioid dependence, and Dr. Sirgo will be providing an update on BUNAVAIL and the anticipated market opportunity.

Additionally, Dr. Sirgo will provide an update on the progress made by BDSI and its commercial partner, Endo Health Solutions, with the ongoing Phase 3 clinical program for BEMA Buprenorphine for the treatment of chronic pain, along with BDSI's recent licensing of Clonidine Topical Gel for the treatment of painful diabetic neuropathy.

The presentation will be webcast live and can be accessed at www.bdsi.com.  For those who are not available to listen to the live broadcast, a replay of the webcast will be available on the BDSI website.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction. 

BDSI's pain franchise consists of three products, two of which utilize the patented BioErodible MucoAdhesive (BEMA) drug delivery technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, E.U. (where it is marketed as BREAKYL) and Taiwan (where it is marketed as PAINKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.). 

BDSI's second pain product using the BEMA technology, BEMA Buprenorphine, is in Phase 3 clinical trials for the treatment of moderate to severe chronic pain and is licensed on a worldwide basis to Endo Health Solutions.  BDSI's third pain product in development is Clonidine Topical Gel for the treatment of painful diabetic neuropathy and was recently licensed from Arcion Therapeutics.

In August 2013, BDSI filed an NDA for BUNAVAIL, a high dose formulation of buprenorphine in combination with naloxone for the maintenance treatment of opioid dependence.  Under the 505(b)(2) regulatory statute, the NDA for BUNAVAIL is subject to a ten month review. 

BDSI's headquarters is located in Raleigh, North Carolina.  For more information visit www.bdsi.com.

Cautionary Note on Forward-Looking Statements

This press release, the presentation referred to herein, and any statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy.  Actual results (including, without limitation, the timing for and results of the clinical trials and proposed NDA submissions for, and FDA review of, the Company's products in development) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  The BioDelivery Sciences logo and BUNAVAIL™ are trademarks owned by BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL™ is a trademark owned by Meda Pharma GmbH & Co. KG.  PAINKYL™ is a trademark owned by TTY Biopharm.  All other trademarks and tradenames are owned by their respective owners.

© BioDelivery Sciences International, Inc.  All rights reserved.


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Endo and BioDelivery Sciences Provide Update on BEMA Buprenorphine Phase III Development Program
2. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2013 Financials
3. BioDelivery Sciences Announces Submission of NDA for BUNAVAIL
4. BioDelivery Sciences Announces the Hiring of Adrian Hepner, M.D. as Vice President of Clinical Research & Regulatory Affairs
5. BioDelivery Sciences to Present at the William Blair 33rd Annual Growth Stock Conference
6. BioDelivery Sciences to Present at the Jefferies 2013 Global Healthcare Conference
7. BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
8. BioDelivery Sciences Appoints Thomas W. DAlonzo to Board of Directors
9. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
10. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
11. BioDelivery Sciences to Host Buprenorphine Investor and Analyst Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Ischemic Stroke Market ... to their offering.       (Logo: ... Global Acute Ischemic Stroke Market and Competitive ... Acute Ischemic Stroke pipeline products, Acute Ischemic ...
(Date:5/3/2016)... May 3, 2016 BioNovus Innovations LLC ... for Advancing Medical Innovation (IAMI) today announced a ... diagnostics and medical devices. An agreement ... rights to license, develop and commercialize medical innovations ... "This partnership represents a significant advance in ...
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Washington Wellness Center today ... central New Jersey residents. What started out as an idea to provide a ... integrated approach to healthcare. , Developed by Dr. David Swanekamp, Chiropractic Physician , ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... for nursing mothers. The company’s patented technology, The Smart Breastfeeding Meter, is designed ... announced that the technology is now available for purchase at Target.com . ...
(Date:5/4/2016)... ... ... Natalie Jill is a well respected lifestyle mentor and fitness ... of her new book: Natalie Jill’s 7 Day Jump Start: Unprocess Your Diet . ... a new healthy lifestyle featuring simple recipes using MitoXcell’s raw cacao formula. , ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Advanced Spine & ... help restore its patients’ health, is hosting a free seminar on stem cell injections. ... held at Advanced Spine & Sport, 4601 Telephone Road, Suite 110, Ventura, CA. There ...
(Date:5/4/2016)... VANCOUVER, British Columbia – , ... ... Wimmzi , a manufacturer of innovative infant and child products, ... teething toys. But their ability to help babies deal with teething ... are FDA approved, contain no toxic gels, and are BPA-, PVC-, ...
Breaking Medicine News(10 mins):